{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:24:51Z","timestamp":1790900691557,"version":"4.1.0"},"reference-count":282,"publisher":"Baishideng Publishing Group Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2008]]},"DOI":"10.3748\/wjg.14.354","type":"journal-article","created":{"date-parts":[[2008,1,19]],"date-time":"2008-01-19T03:03:55Z","timestamp":1200711835000},"page":"354","source":"Crossref","is-referenced-by-count":187,"title":["Treatment of inflammatory bowel disease: A review of medical therapy"],"prefix":"10.3748","volume":"14","author":[{"given":"Patricia L","family":"Kozuch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B","family":"Hanauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther 2006;24 Suppl 1:2-9.","DOI":"10.1111\/j.1365-2036.2006.03069.x"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Harrell LE, Hanauer SB. Mesalamine derivatives in the treatment of Crohn's disease. Gastroenterol Clin North Am 2004;33:303-317, ix-x.","DOI":"10.1016\/j.gtc.2004.02.010"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, Singleton JW. National Cooperative Crohn&rsquo;s Disease Study: results of drug treatment. Gastroenterology 1979;77:847-869.","DOI":"10.1016\/0016-5085(79)90385-8"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H. European Cooperative Crohn&rsquo;s Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-266.","DOI":"10.1016\/0016-5085(84)90409-8"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, Krawitt EL. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 1993;104:1293-1301.","DOI":"10.1016\/0016-5085(93)90337-C"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004;2:379-388.","DOI":"10.1016\/S1542-3565(04)00122-3"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Feagan BG. Review article: mild to moderate Crohn&rsquo;s disease--defining the basis for a new treatment algorithm. Aliment Pharmacol Ther 2003;18:263-277.","DOI":"10.1046\/j.1365-2036.2003.01661.x"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Prantera C, Cottone M, Pallone F, Annese V, Franze A, Cerutti R, Bianchi Porro G. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Gastroenterology 1999;116:521-526.","DOI":"10.1016\/S0016-5085(99)70172-1"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 1994;19:278-282.","DOI":"10.1097\/00004836-199412000-00003"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998;339:370-374.","DOI":"10.1056\/NEJM199808063390603"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Colombel JF, Lemann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas JL, Notteghem B, Mary JY. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999;94:674-678.","DOI":"10.1111\/j.1572-0241.1999.935_q.x"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Lennard-Jones JE. Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial. Gut 1977;18:69-72.","DOI":"10.1136\/gut.18.1.69"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Gisbert JP, Gomollon F, Mate J, Pajares JM. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci 2002;47:471-488.","DOI":"10.1023\/A:1017987229718"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Cochrane Database Syst Rev 2005;CD003715.","DOI":"10.1002\/14651858.CD003715.pub2"},{"key":"ref15","unstructured":"Gendre JP, Mary JY, Florent C, Modigliani R, Colombel JF, Soule JC, Galmiche JP, Lerebours E, Descos L, Viteau JM. Maintenance treatment of Crohn's disease using orally administered mesalazine (Pentasa). A controlled multicenter study. The Study Groups on the Treatment of Inflammatory Digestive Disorders. Ann Gastroenterol Hepatol (Paris) 1993;29:251-256."},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Modigliani R, Colombel JF, Dupas JL, Dapoigny M, Costil V, Veyrac M, Duclos B, Soule JC, Gendre JP, Galmiche JP. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1996;110:688-693.","DOI":"10.1053\/gast.1996.v110.pm8608877"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Achkar JP, Hanauer SB. Medical therapy to reduce postoperative Crohn&rsquo;s disease recurrence. Am J Gastroenterol 2000;95:1139-1146.","DOI":"10.1111\/j.1572-0241.2000.02000.x"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn&rsquo;s disease. Gastroenterology 1990;99:956-963.","DOI":"10.1016\/0016-5085(90)90613-6"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn&rsquo;s disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997;113:1465-1473.","DOI":"10.1053\/gast.1997.v113.pm9352848"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Lochs H, Mayer M, Fleig WE, Mortensen PB, Bauer P, Genser D, Petritsch W, Raithel M, Hoffmann R, Gross V. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 2000;118:264-273.","DOI":"10.1016\/S0016-5085(00)70208-3"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Sutherland LR. Mesalamine for the prevention of postoperative recurrence: is nearly there the same as being there? Gastroenterology 2000;118:436-438.","DOI":"10.1016\/S0016-5085(00)70227-7"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, Present DH. Postoperative maintenance of Crohn&rsquo;s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004;127:723-729.","DOI":"10.1053\/j.gastro.2004.06.002"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers R, Mekhjian H, Greenberger N, Kelly M. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991;32:1071-1075.","DOI":"10.1136\/gut.32.9.1071"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Blichfeldt P, Blomhoff JP, Myhre E, Gjone E. Metronidazole in Crohn's disease. A double blind cross-over clinical trial. Scand J Gastroenterol 1978;13:123-127.","DOI":"10.3109\/00365527809179816"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, Seidman E, Leddin DJ, Bitton A, Drouin E. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002;123:33-40.","DOI":"10.1053\/gast.2002.34225"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002;8:10-15.","DOI":"10.1097\/00054725-200201000-00002"},{"key":"ref27","unstructured":"Ursing B. Treatment of Crohn disease with metronidazole. A Swedish multicentre study. Lakartidningen 1982;79:543-545."},{"key":"ref28","unstructured":"Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, Luzi C. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91:328-332."},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F, Cottone M. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006;23:1117-1125.","DOI":"10.1111\/j.1365-2036.2006.02879.x"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980;79:357-365.","DOI":"10.1016\/0016-5085(80)90155-9"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982;83:383-387.","DOI":"10.1016\/S0016-5085(82)80332-6"},{"key":"ref32","unstructured":"Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984;79:533-540."},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-1621.","DOI":"10.1016\/0016-5085(95)90121-3"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Rutgeerts P, Van Assche G, Vermeire S, D'Haens G, Baert F, Noman M, Aerden I, De Hertogh G, Geboes K, Hiele M. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005;128:856-861.","DOI":"10.1053\/j.gastro.2005.01.010"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Katz JA. Treatment of inflammatory bowel disease with corticosteroids. Gastroenterol Clin North Am 2004;33:171-189, vii.","DOI":"10.1016\/j.gtc.2004.02.002"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-260.","DOI":"10.1053\/gast.2001.26279"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn&rsquo;s disease. Gut 1994;35:360-362.","DOI":"10.1136\/gut.35.3.360"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Hanauer SB. The 'tipping point' applied. Nat Clin Pract Gastroenterol Hepatol 2006;3:59.","DOI":"10.1038\/ncpgasthep0411"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006;130:650-656.","DOI":"10.1053\/j.gastro.2005.12.019"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Rutgeerts P, Lofberg R, Malchow H, Lamers C, Olaison G, Jewell D, Danielsson A, Goebell H, Thomsen OO, Lorenz-Meyer H. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-845.","DOI":"10.1056\/NEJM199409293311304"},{"key":"ref41","unstructured":"Gross V, Andus T, Caesar I, Bischoff SC, Lochs H, Tromm A, Schulz HJ, Bar U, Weber A, Gierend M. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German\/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol 1996;8:905-909."},{"key":"ref42","unstructured":"Bello C, Goldstein F, Thornton JJ. Alternate-day prednisone treatment and treatment maintenance in Crohn's disease. Am J Gastroenterol 1991;86:460-466."},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Bergman L, Krause U. Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radical resection for Crohn's disease. Scand J Gastroenterol 1976;11:651-656.","DOI":"10.1080\/00365521.1976.12097167"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2003;CD000301.","DOI":"10.1002\/14651858.CD000301"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG. The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther 2002;16:1509-1517.","DOI":"10.1046\/j.1365-2036.2002.01289.x"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Otley A, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2005;CD000296.","DOI":"10.1002\/14651858.CD000296.pub2"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994;331:836-841.","DOI":"10.1056\/NEJM199409293311303"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Tremaine WJ, Hanauer SB, Katz S, Winston BD, Levine JG, Persson T, Persson A. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002;97:1748-1754.","DOI":"10.1111\/j.1572-0241.2002.05835.x"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Herfarth H, Gross V, Andus T, Caesar I, Vogelsang H, Adler G, Malchow H, Petri A, Gierend M, Scholmerich J. Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization. Int J Colorectal Dis 2004;19:147-152.","DOI":"10.1007\/s00384-003-0529-5"},{"key":"ref50","unstructured":"Bar-Meir S, Chowers Y, Lavy A, Abramovitch D, Sternberg A, Leichtmann G, Reshef R, Odes S, Moshkovitz M, Bruck R. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology 1998;115:835-840."},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997;41:209-214.","DOI":"10.1136\/gut.41.2.209"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Papi C, Luchetti R, Gili L, Montanti S, Koch M, Capurso L. Budesonide in the treatment of Crohn's disease: a meta-analysis. Aliment Pharmacol Ther 2000;14:1419-1428.","DOI":"10.1046\/j.1365-2036.2000.00867.x"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Gross V, Andus T, Ecker KW, Raedler A, Loeschke K, Plauth M, Rasenack J, Weber A, Gierend M, Ewe K. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group. Gut 1998;42:493-496.","DOI":"10.1136\/gut.42.4.493"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther 2005;21:363-371.","DOI":"10.1111\/j.1365-2036.2005.02338.x"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Lofberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 2005;100:1780-1787.","DOI":"10.1111\/j.1572-0241.2005.41992.x"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 1996;110:45-51.","DOI":"10.1053\/gast.1996.v110.pm8536887"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Ferguson A, Campieri M, Doe W, Persson T, Nygard G. Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group. Aliment Pharmacol Ther 1998;12:175-183.","DOI":"10.1046\/j.1365-2036.1998.00285.x"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Ewe K, Bottger T, Buhr HJ, Ecker KW, Otto HF. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group. Eur J Gastroenterol Hepatol 1999;11:277-282.","DOI":"10.1097\/00042737-199903000-00011"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Hellers G, Cortot A, Jewell D, Leijonmarck CE, Lofberg R, Malchow H, Nilsson LG, Pallone F, Pena S, Persson T. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology 1999;116:294-300.","DOI":"10.1016\/S0016-5085(99)70125-3"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Simms L, Steinhart AH. Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2001;CD002913.","DOI":"10.1002\/14651858.CD002913"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Schoon EJ, Bollani S, Mills PR, Israeli E, Felsenberg D, Ljunghall S, Persson T, Hapten-White L, Graffner H, Bianchi Porro G. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol 2005;3:113-121.","DOI":"10.1016\/S1542-3565(04)00662-7"},{"key":"ref62","unstructured":"Lichtenstein G, Hapten-White L, Sandborn WJ. Long-term safety analysis of budesonide in Crohn&lsquo;s disease: a pooled analysis of five 1-year studies. Gastroenterology 2006;130:A484."},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Schroll S, Sarlette A, Ahrens K, Manns MP, Goke M. Effects of azathioprine and its metabolites on repair mechanisms of the intestinal epithelium in vitro. Regul Pept 2005;131:1-11.","DOI":"10.1016\/j.regpep.2005.03.001"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111:1133-1145.","DOI":"10.1172\/JCI16432"},{"key":"ref65","unstructured":"Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000;CD000545."},{"key":"ref66","unstructured":"Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000;CD000067."},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302:981-987.","DOI":"10.1056\/NEJM198005013021801"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-678.","DOI":"10.1136\/gut.37.5.674"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Vilien M, Dahlerup JF, Munck LK, Norregaard P, Gronbaek K, Fallingborg J. Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year. Aliment Pharmacol Ther 2004;19:1147-1152.","DOI":"10.1111\/j.1365-2036.2004.01944.x"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Lemann M, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, Modigliani R, Bouhnik Y. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005;128:1812-1818.","DOI":"10.1053\/j.gastro.2005.03.031"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Ardizzone S, Maconi G, Sampietro GM, Russo A, Radice E, Colombo E, Imbesi V, Molteni M, Danelli PG, Taschieri AM. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004;127:730-740.","DOI":"10.1053\/j.gastro.2004.06.051"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Holtmann MH, Krummenauer F, Claas C, Kremeyer K, Lorenz D, Rainer O, Vogel I, Bocker U, Bohm S, Buning C. Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients. Dig Dis Sci 2006;51:1516-1524.","DOI":"10.1007\/s10620-005-9037-5"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.","DOI":"10.1053\/gast.2000.18144"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-1125.","DOI":"10.1136\/gut.2004.049460"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Disanti W, Rajapakse RO, Korelitz BI, Panagopoulos G, Bratcher J. Incidence of neoplasms in patients who develop sustained leukopenia during or after treatment with 6-mercaptopurine for inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4:1025-1029.","DOI":"10.1016\/j.cgh.2006.03.018"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Dayharsh GA, Loftus EV Jr, Sandborn WJ, Tremaine WJ, Zinsmeister AR, Witzig TE, Macon WR, Burgart LJ. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002;122:72-77.","DOI":"10.1053\/gast.2002.30328"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther 2005;22:1-16.","DOI":"10.1111\/j.1365-2036.2005.02520.x"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Pierik M, Rutgeerts P, Vlietinck R, Vermeire S. Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol 2006;12:3657-3667.","DOI":"10.3748\/wjg.v12.i23.3657"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Baron TH, Truss CD, Elson CO. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 1993;38:1851-1856.","DOI":"10.1007\/BF01296109"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353-356.","DOI":"10.7326\/0003-4819-110-5-353"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292-297.","DOI":"10.1056\/NEJM199502023320503"},{"key":"ref82","unstructured":"Oren R, Moshkowitz M, Odes S, Becker S, Keter D, Pomeranz I, Shirin C, Reisfeld I, Broide E, Lavy A. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997;92:2203-2209."},{"key":"ref83","unstructured":"Arora S, Katkov W, Cooley J, Kemp JA, Johnston DE, Schapiro RH, Podolsky D. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999;46:1724-1729."},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Kurnik D, Loebstein R, Fishbein E, Almog S, Halkin H, Bar-Meir S, Chowers Y. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther 2003;18:57-63.","DOI":"10.1046\/j.1365-2036.2003.01614.x"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther 2001;15:35-44.","DOI":"10.1046\/j.1365-2036.2001.00908.x"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Hayee BH, Harris AW. Methotrexate for Crohn's disease: experience in a district general hospital. Eur J Gastroenterol Hepatol 2005;17:893-898.","DOI":"10.1097\/00042737-200509000-00002"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Lemann M, Chamiot-Prieur C, Mesnard B, Halphen M, Messing B, Rambaud JC, Gendre JP, Colombel JF, Modigliani R. Methotrexate for the treatment of refractory Crohn's disease. Aliment Pharmacol Ther 1996;10:309-314.","DOI":"10.1111\/j.0953-0673.1996.00309.x"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis 2003;35:619-627.","DOI":"10.1016\/S1590-8658(03)00372-4"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000;12:1227-1233.","DOI":"10.1097\/00042737-200012110-00010"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-1632.","DOI":"10.1056\/NEJM200006013422202"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Fraser AG, Morton D, McGovern D, Travis S, Jewell DP. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:693-697.","DOI":"10.1046\/j.1365-2036.2002.01227.x"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer zum Buschenfelde KH, Schlaak JF. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 1999;44:625-628.","DOI":"10.1136\/gut.44.5.625"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Loftus CG, Egan LJ, Sandborn WJ. Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am 2004;33:141-169, vii.","DOI":"10.1016\/j.gtc.2004.02.001"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Gonzalez-Lama Y, Gisbert JP, Mate J. The role of tacrolimus in inflammatory bowel disease: a systematic review. Dig Dis Sci 2006;51:1833-1840.","DOI":"10.1007\/s10620-006-9209-y"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-1035.","DOI":"10.1056\/NEJM199710093371502"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-769.","DOI":"10.1016\/S0016-5085(99)70332-X"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-1549.","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006;63:433-442; quiz 464.","DOI":"10.1016\/j.gie.2005.08.011"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-1405.","DOI":"10.1056\/NEJM199905063401804"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE. Infliximab maintenance therapy for fistulizing Crohn&rsquo;s disease. N Engl J Med 2004;350:876-885.","DOI":"10.1056\/NEJMoa030815"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Domenech E, Hinojosa J, Nos P, Garcia-Planella E, Cabre E, Bernal I, Gassull MA. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? Aliment Pharmacol Ther 2005;22:1107-1113.","DOI":"10.1111\/j.1365-2036.2005.02670.x"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"Baert F, Noman M, Vermeire S, Van Assche G, D&rsquo; Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-608.","DOI":"10.1056\/NEJMoa020888"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn&rsquo;s disease: a randomized controlled trial. Gastroenterology 2003;124:917-924.","DOI":"10.1053\/gast.2003.50145"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn&rsquo;s disease: a user's guide for clinicians. Am J Gastroenterol 2002;97:2962-2972.","DOI":"10.1111\/j.1572-0241.2002.07093.x"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Aliment Pharmacol Ther 2006;23:451-463.","DOI":"10.1111\/j.1365-2036.2006.02786.x"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"Schroder O, Blumenstein I, Stein J. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn&rsquo;s disease: a controlled pilot study. Eur J Gastroenterol Hepatol 2006;18:11-16.","DOI":"10.1097\/00042737-200601000-00003"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003;17:1451-1457.","DOI":"10.1046\/j.1365-2036.2003.01574.x"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Parsi MA, Achkar JP, Richardson S, Katz J, Hammel JP, Lashner BA, Brzezinski A. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002;123:707-713.","DOI":"10.1053\/gast.2002.35390"},{"key":"ref109","doi-asserted-by":"crossref","unstructured":"Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002;97:2357-2363.","DOI":"10.1111\/j.1572-0241.2002.05991.x"},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"Lemann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006;130:1054-1061.","DOI":"10.1053\/j.gastro.2006.02.014"},{"key":"ref111","unstructured":"Hommes D, Baert F, van Assche G, Caenepeel , Vergauwe P, Tuynman H, de Vos M, van Deventer S, Stitt L, Rutgeerts P. The ideal management of Crohn&rsquo;s disease: top down versus step up strategies, a randomized controlled trial. Gastroenterology 2006;130:A108."},{"key":"ref112","doi-asserted-by":"crossref","unstructured":"Caprilli R, Angelucci E, Cocco A. Early or late guided missile in the treatment of Crohn's disease? Dig Liver Dis 2005;37:973-979.","DOI":"10.1016\/j.dld.2005.07.003"},{"key":"ref113","doi-asserted-by":"crossref","unstructured":"Loftus EV. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: \"lifetime use\" is an awfully long time. Am J Gastroenterol 2005;100:1435-1438.","DOI":"10.1111\/j.1572-0241.2005.50622_2.x"},{"key":"ref114","doi-asserted-by":"crossref","unstructured":"Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.","DOI":"10.1053\/j.gastro.2003.10.047"},{"key":"ref115","doi-asserted-by":"crossref","unstructured":"Askling J, Brandt L, Lapidus A, Karlen P, Bjorkholm M, Lofberg R, Ekbom A. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005;54:617-622.","DOI":"10.1136\/gut.2004.051771"},{"key":"ref116","doi-asserted-by":"crossref","unstructured":"Greenstein AJ, Gennuso R, Sachar DB, Heimann T, Smith H, Janowitz HD, Aufses AH Jr. Extraintestinal cancers in inflammatory bowel disease. Cancer 1985;56:2914-2921.","DOI":"10.1002\/1097-0142(19851215)56:12<2914::AID-CNCR2820561232>3.0.CO;2-J"},{"key":"ref117","doi-asserted-by":"crossref","unstructured":"Ekbom A, Helmick C, Zack M, Adami HO. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991;67:2015-2019.","DOI":"10.1002\/1097-0142(19910401)67:7<2015::AID-CNCR2820670731>3.0.CO;2-R"},{"key":"ref118","unstructured":"Lichtenstein GR, Cohen RD, Feagan BG, Sandborn WJ, Salzberg BA, Chen DM, Pritchard ML, Broussard DL, Diamond RH. Safety of infliximab and other Crohn&rsquo;s disease therapies: TREAT registry data with nearly 15,000 patient-years of follow-up. Gastroenterology 2006;130:A71."},{"key":"ref119","doi-asserted-by":"crossref","unstructured":"Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1017-1024; quiz 976.","DOI":"10.1016\/j.cgh.2006.05.020"},{"key":"ref120","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Hanauer S, Loftus EV Jr, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004;99:1984-1989.","DOI":"10.1111\/j.1572-0241.2004.40462.x"},{"key":"ref121","doi-asserted-by":"crossref","unstructured":"Papadakis KA, Shaye OA, Vasiliauskas EA, Ippoliti A, Dubinsky MC, Birt J, Paavola J, Lee SK, Price J, Targan SR. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005;100:75-79.","DOI":"10.1111\/j.1572-0241.2005.40647.x"},{"key":"ref122","doi-asserted-by":"crossref","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-333; quiz 591.","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"ref123","unstructured":"Rutgeerts PJ, Mellili LE, Li J, Pollack PF. Adalimumab maintains improvement in inflammatory bowel disease questionnaire (IBDQ) scores over 1 year following the initial attainment of remisssion in patients with moderately severely active Crohn&rsquo;s disease: results of the CLASSIC II study. Gastroenterology 2006;130:A479."},{"key":"ref124","doi-asserted-by":"crossref","unstructured":"Panaccione R, Hanauer SB, Fedorak R, Rutgeerts P, Sandborn WJ, Pollack P. Concomitant immunosuppressive and adalimumab therapy in patients with Crohn&rsquo;s disease: 1-year results of the CLASSIC II study. Gastroenterology 2006;130:A479.","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"ref125","doi-asserted-by":"crossref","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.","DOI":"10.1053\/j.gastro.2006.11.041"},{"key":"ref126","doi-asserted-by":"crossref","unstructured":"Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OO, Innes A. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-818.","DOI":"10.1053\/j.gastro.2005.06.064"},{"key":"ref127","doi-asserted-by":"crossref","unstructured":"Winter TA, Wright J, Ghosh S, Jahnsen J, Innes A, Round P. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther 2004;20:1337-1346.","DOI":"10.1111\/j.1365-2036.2004.02285.x"},{"key":"ref128","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, CJ , Panes J, Scholmerich J, McColm JA, Schreiber S. Higher remission and maintenance of response rates with subcutaneous monthly certolizumab pegol in patients with recent-onset Crohn&rsquo;s disease: data from PRECiSE 2. Am J Gastroenterol 2006;101:S454-S455.","DOI":"10.14309\/00000434-200609001-01109"},{"key":"ref129","doi-asserted-by":"crossref","unstructured":"Hommes DW, Mikhajlova TL, Stoinov S, Stimac D, Vucelic B, Lonovics J, Zakuciova M, D'Haens G, Van Assche G, Ba S. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006;55:1131-1137.","DOI":"10.1136\/gut.2005.079392"},{"key":"ref130","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Yednock TA. Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol 2003;98:2372-2382.","DOI":"10.1111\/j.1572-0241.2003.08703.x"},{"key":"ref131","doi-asserted-by":"crossref","unstructured":"Kent SJ, Karlik SJ, Cannon C, Hines DK, Yednock TA, Fritz LC, Horner HC. A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 1995;58:1-10.","DOI":"10.1016\/0165-5728(94)00165-K"},{"key":"ref132","doi-asserted-by":"crossref","unstructured":"Hesterberg PE, Winsor-Hines D, Briskin MJ, Soler-Ferran D, Merrill C, Mackay CR, Newman W, Ringler DJ. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 1996;111:1373-1380.","DOI":"10.1053\/gast.1996.v111.pm8898653"},{"key":"ref133","doi-asserted-by":"crossref","unstructured":"Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32.","DOI":"10.1056\/NEJMoa020732"},{"key":"ref134","doi-asserted-by":"crossref","unstructured":"Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, Donoghue S, Greenlees C, Subhani J, Amlot PL. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-274.","DOI":"10.1053\/gast.2001.26260"},{"key":"ref135","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-1925.","DOI":"10.1056\/NEJMoa043335"},{"key":"ref136","unstructured":"Targan SR, Feagan B, Fedorak R, Lashner B, Panacionne R, Present D, Raedler A, Rutgeerts P, Tulassay Z, Volfova M. Natalizumab induces sustained response and remission in patients with active Crohn&rsquo;s disease: results from the ENCORE trial. Gastroenterology 2006;130:A108."},{"key":"ref137","unstructured":"Sandborn W, Colombel JF, Enns R, Feagan B, Hanauer S, Lawrance I, Panaccione R, Rutgeerts P, Schreiber S, Targan S. Maintenance therapy with natalizumab does not require use of concomitant immunosuppressants for sustained efficacy in patients with active Crohn&rsquo;s disease: results from the ENACT-2 study. Gastroenterology 2006;130:A482."},{"key":"ref138","doi-asserted-by":"crossref","unstructured":"Panaccione R, Colombel JF, Enns R, Feagan B, Hanauer S, Lawrance I, Rutgeerts P, Sandborn S, Schreiber S, Targan S. Natalizumab maintains remission in patients with moderately to severely active Crohn&rsquo;s disease for up to 2 years: results from an open-label extension study. Gastroenterology 2006;130:A111.","DOI":"10.14309\/00000434-200609001-01152"},{"key":"ref139","unstructured":"Sandborn W, Targan S. A safety evaluation for progressive multifocal leukoencephalopathy (PML) in greater than 3,500 patients with Crohn&rsquo;s disease (CD), multiple sclerosis (MS), and rheumatoid arthritis (RA) previously treated with natalizumab in clinical trials. Gastroenterology 2006;130:A72."},{"key":"ref140","doi-asserted-by":"crossref","unstructured":"Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, Dube R, Cohen A, Steinhart AH, Landau S. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352:2499-2507.","DOI":"10.1056\/NEJMoa042982"},{"key":"ref141","unstructured":"Lindenboom K, Brazier G. Millennium pharmaceuticals announces phase II data for MLN02 in Crohn&rsquo;s disease Cambridge, MA: Millennium PharmaceuticalsCambridge, MA; 2002;."},{"key":"ref142","unstructured":"Hommes D, Targan S, Baumgart DC, Dignass AU, Mayer L, Lowder JN. A Phase I Study: Visilizumab therapy in Crohn&rsquo;s disease (CD) patients refractory to infliximab treatment. Gastroenterology 2006;130:A111."},{"key":"ref143","doi-asserted-by":"crossref","unstructured":"Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126:989-996; discussion 947.","DOI":"10.1053\/j.gastro.2004.01.012"},{"key":"ref144","doi-asserted-by":"crossref","unstructured":"Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B, Goodman N, Groden C, Hornung RL. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351:2069-2079.","DOI":"10.1056\/NEJMoa033402"},{"key":"ref145","doi-asserted-by":"crossref","unstructured":"Bariol C, Meagher AP, Vickers CR, Byrnes DJ, Edwards PD, Hing M, Wettstein AR, Field A. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol 2002;17:135-139.","DOI":"10.1046\/j.1440-1746.2002.02564.x"},{"key":"ref146","doi-asserted-by":"crossref","unstructured":"Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 2002;50:196-200.","DOI":"10.1136\/gut.50.2.196"},{"key":"ref147","doi-asserted-by":"crossref","unstructured":"Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ. Sargramostim for active Crohn's disease. N Engl J Med 2005;352:2193-2201.","DOI":"10.1056\/NEJMoa041109"},{"key":"ref148","doi-asserted-by":"crossref","unstructured":"Rioux KP, Fedorak RN. Probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2006;40:260-363.","DOI":"10.1097\/00004836-200603000-00019"},{"key":"ref149","doi-asserted-by":"crossref","unstructured":"Summers RW, Elliott DE, Urban JF Jr, Thompson R, Weinstock JV. Trichuris suis therapy in Crohn's disease. Gut 2005;54:87-90.","DOI":"10.1136\/gut.2004.041749"},{"key":"ref150","doi-asserted-by":"crossref","unstructured":"Nielsen OH. Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand J Gastroenterol 1982;17:389-393.","DOI":"10.3109\/00365528209182073"},{"key":"ref151","doi-asserted-by":"crossref","unstructured":"Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;CD000543.","DOI":"10.1002\/14651858.CD000543.pub2"},{"key":"ref152","doi-asserted-by":"crossref","unstructured":"Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;CD000544.","DOI":"10.1002\/14651858.CD000544.pub2"},{"key":"ref153","doi-asserted-by":"crossref","unstructured":"Green JR, Lobo AJ, Holdsworth CD, Leicester RJ, Gibson JA, Kerr GD, Hodgson HJ, Parkins KJ, Taylor MD. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology 1998;114:15-22.","DOI":"10.1016\/S0016-5085(98)70627-4"},{"key":"ref154","unstructured":"Levine DS, Riff DS, Pruitt R, Wruble L, Koval G, Sales D, Bell JK, Johnson LK. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002;97:1398-1407."},{"key":"ref155","doi-asserted-by":"crossref","unstructured":"Pruitt R, Hanson J, Safdi M, Wruble L, Hardi R, Johanson J, Koval G, Riff D, Winston B, Cross A. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002;97:3078-3086.","DOI":"10.1111\/j.1572-0241.2002.07103.x"},{"key":"ref156","doi-asserted-by":"crossref","unstructured":"Sandborn WJ. Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. Am J Gastroenterol 2002;97:2939-2941.","DOI":"10.1111\/j.1572-0241.2002.07092.x"},{"key":"ref157","doi-asserted-by":"crossref","unstructured":"Hanauer SB. Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis. Gut 1999;44:455.","DOI":"10.1136\/gut.44.4.455"},{"key":"ref158","doi-asserted-by":"crossref","unstructured":"Gross V. Efficacy of different mesalamine-releasing drugs. Gastroenterology 1998;115:1306-1307.","DOI":"10.1016\/S0016-5085(98)70119-2"},{"key":"ref159","doi-asserted-by":"crossref","unstructured":"Hanauer SB. Treatment of ulcerative colitis with balsalazide: response to Drs Johnson, Green, and Pruitt. Am J Gastroenterol 2003;98:697-698.","DOI":"10.1111\/j.1572-0241.2003.07323.x"},{"key":"ref160","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Hanauer SB, Buch A. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Aliment Pharmacol Ther 2004;19:1089-1098.","DOI":"10.1111\/j.1365-2036.2004.01964.x"},{"key":"ref161","doi-asserted-by":"crossref","unstructured":"Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F. Delayed-release oral mesalamine at 4.8 g\/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005;100:2478-2485.","DOI":"10.1111\/j.1572-0241.2005.00248.x"},{"key":"ref162","doi-asserted-by":"crossref","unstructured":"Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007;5:95-102.","DOI":"10.1016\/j.cgh.2006.10.025"},{"key":"ref163","doi-asserted-by":"crossref","unstructured":"Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000;95:1263-1276.","DOI":"10.1111\/j.1572-0241.2000.01940.x"},{"key":"ref164","doi-asserted-by":"crossref","unstructured":"Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 2000;95:1628-1636.","DOI":"10.1111\/j.1572-0241.2000.02180.x"},{"key":"ref165","doi-asserted-by":"crossref","unstructured":"Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041-1048.","DOI":"10.1136\/bmj.2.4947.1041"},{"key":"ref166","doi-asserted-by":"crossref","unstructured":"Baron JH, Connell AM, Kanaghinis TG, Lennard-Jones JE, Jones AF. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J 1962;2:441-443.","DOI":"10.1136\/bmj.2.5302.441"},{"key":"ref167","doi-asserted-by":"crossref","unstructured":"Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978;13:833-837.","DOI":"10.3109\/00365527809182199"},{"key":"ref168","doi-asserted-by":"crossref","unstructured":"Sood A, Midha V, Sood N, Awasthi G. A prospective, open-label trial assessing dexamethasone pulse therapy in moderate to severe ulcerative colitis. J Clin Gastroenterol 2002;35:328-331.","DOI":"10.1097\/00004836-200210000-00009"},{"key":"ref169","doi-asserted-by":"crossref","unstructured":"Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007;5:103-110.","DOI":"10.1016\/j.cgh.2006.09.033"},{"key":"ref170","doi-asserted-by":"crossref","unstructured":"Bossa F, Fiorella S, Caruso N, Accadia L, Napolitano G, Valvano MR, Andriulli A, Annese V. Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. Am J Gastroenterol 2007;102:601-608.","DOI":"10.1111\/j.1572-0241.2006.01007.x"},{"key":"ref171","doi-asserted-by":"crossref","unstructured":"Kjeldsen J. Treatment of ulcerative colitis with high doses of oral prednisolone. The rate of remission, the need for surgery, and the effect of prolonging the treatment. Scand J Gastroenterol 1993;28:821-826.","DOI":"10.3109\/00365529309104016"},{"key":"ref172","doi-asserted-by":"crossref","unstructured":"Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005-1013.","DOI":"10.1016\/0016-5085(85)90201-X"},{"key":"ref173","doi-asserted-by":"crossref","unstructured":"Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, Jewell DP. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-910.","DOI":"10.1136\/gut.38.6.905"},{"key":"ref174","doi-asserted-by":"crossref","unstructured":"Honda M, Orii F, Ayabe T, Imai S, Ashida T, Obara T, Kohgo Y. Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 2000;118:859-866.","DOI":"10.1016\/S0016-5085(00)70172-7"},{"key":"ref175","doi-asserted-by":"crossref","unstructured":"Zhang H, Ouyang Q, Wen ZH, Fiocchi C, Liu WP, Chen DY, Li FY. Significance of glucocorticoid receptor expression in colonic mucosal cells of patients with ulcerative colitis. World J Gastroenterol 2005;11:1775-1778.","DOI":"10.3748\/wjg.v11.i12.1775"},{"key":"ref176","doi-asserted-by":"crossref","unstructured":"Webster JC, Oakley RH, Jewell CM, Cidlowski JA. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance. Proc Natl Acad Sci USA 2001;98:6865-6870.","DOI":"10.1073\/pnas.121455098"},{"key":"ref177","unstructured":"Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974;1:1067-1070."},{"key":"ref178","doi-asserted-by":"crossref","unstructured":"Lofberg R, Danielsson A, Suhr O, Nilsson A, Schioler R, Nyberg A, Hultcrantz R, Kollberg B, Gillberg R, Willen R. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996;110:1713-1718.","DOI":"10.1053\/gast.1996.v110.pm8964395"},{"key":"ref179","doi-asserted-by":"crossref","unstructured":"Campieri M, Adamo S, Valpiani D, D'Arienzo A, D&rsquo;Albasio G, Pitzalis M, Cesari P, Casetti T, Castiglione GN, Rizzello F. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther 2003;17:1471-1480.","DOI":"10.1046\/j.1365-2036.2003.01609.x"},{"key":"ref180","doi-asserted-by":"crossref","unstructured":"Rizzello F, Gionchetti P, D'Arienzo A, Manguso F, Di Matteo G, Annese V, Valpiani D, Casetti T, Adamo S, Prada A. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2002;16:1109-1116.","DOI":"10.1046\/j.1365-2036.2002.01298.x"},{"key":"ref181","doi-asserted-by":"crossref","unstructured":"Hanauer SB, Robinson M, Pruitt R, Lazenby AJ, Persson T, Nilsson LG, Walton-Bowen K, Haskell LP, Levine JG. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. Gastroenterology 1998;115:525-532.","DOI":"10.1016\/S0016-5085(98)70131-3"},{"key":"ref182","doi-asserted-by":"crossref","unstructured":"Lindgren S, Lofberg R, Bergholm L, Hellblom M, Carling L, Ung KA, Schioler R, Unge P, Wallin C, Strom M. Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis. Scand J Gastroenterol 2002;37:705-710.","DOI":"10.1080\/00365520212512"},{"key":"ref183","doi-asserted-by":"crossref","unstructured":"Lemann M, Galian A, Rutgeerts P, Van Heuverzwijn R, Cortot A, Viteau JM, Elewaut A, Belaiche J, Froguel E, Modigliani R. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1995;9:557-562.","DOI":"10.1111\/j.1365-2036.1995.tb00421.x"},{"key":"ref184","doi-asserted-by":"crossref","unstructured":"Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as positive control. The Danish Budesonide Study Group. Scand J Gastroenterol 1991;26:1225-1230.","DOI":"10.3109\/00365529108998618"},{"key":"ref185","doi-asserted-by":"crossref","unstructured":"Danielsson A, Hellers G, Lyrenas E, Lofberg R, Nilsson A, Olsson O, Olsson SA, Persson T, Salde L, Naesdal J. A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol 1987;22:987-992.","DOI":"10.3109\/00365528708991947"},{"key":"ref186","doi-asserted-by":"crossref","unstructured":"Lofberg R, Ostergaard Thomsen O, Langholz E, Schioler R, Danielsson A, Suhr O, Graffner H, Pahlman L, Matzen P, Moller-Petersen JF. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1994;8:623-629.","DOI":"10.1111\/j.1365-2036.1994.tb00340.x"},{"key":"ref187","doi-asserted-by":"crossref","unstructured":"Gross V, Bar-Meir S, Lavy A, Mickisch O, Tulassay Z, Pronai L, Kupcinskas L, Kiudelis G, Pokrotnieks J, Kovacs A. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther 2006;23:303-312.","DOI":"10.1111\/j.1365-2036.2006.02743.x"},{"key":"ref188","doi-asserted-by":"crossref","unstructured":"Mulder CJ, Fockens P, Meijer JW, van der Heide H, Wiltink EH, Tytgat GN. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg\/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996;8:549-553.","DOI":"10.1097\/00042737-199606000-00010"},{"key":"ref189","doi-asserted-by":"crossref","unstructured":"Campieri M, Cottone M, Miglio F, Manenti F, Astegiano M, D'Arienzo A, Manguso F, D'Albasio G, Bonanomi A, Galeazzi R. Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis. Aliment Pharmacol Ther 1998;12:361-366.","DOI":"10.1046\/j.1365-2036.1998.00299.x"},{"key":"ref190","doi-asserted-by":"crossref","unstructured":"Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974;4:627-630.","DOI":"10.1136\/bmj.4.5945.627"},{"key":"ref191","doi-asserted-by":"crossref","unstructured":"Rosenberg JL, Wall AJ, Levin B, Binder HJ, Kirsner JB. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975;69:96-99.","DOI":"10.1016\/S0016-5085(19)32641-1"},{"key":"ref192","doi-asserted-by":"crossref","unstructured":"Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed) 1982;284:1291-1292.","DOI":"10.1136\/bmj.284.6325.1291"},{"key":"ref193","doi-asserted-by":"crossref","unstructured":"Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbri ck ET, Scott BB, Lennard-Jones JE. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992;305:20-22.","DOI":"10.1136\/bmj.305.6844.20"},{"key":"ref194","unstructured":"Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990;85:717-722."},{"key":"ref195","unstructured":"George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996;91:1711-1714."},{"key":"ref196","doi-asserted-by":"crossref","unstructured":"Ardizzone S, Molteni P, Imbesi V, Bollani S, Bianchi Porro G. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997;25:330-333.","DOI":"10.1097\/00004836-199707000-00007"},{"key":"ref197","doi-asserted-by":"crossref","unstructured":"Lobo AJ, Foster PN, Burke DA, Johnston D, Axon AT. The role of azathioprine in the management of ulcerative colitis. Dis Colon Rectum 1990;33:374-377.","DOI":"10.1007\/BF02156261"},{"key":"ref198","doi-asserted-by":"crossref","unstructured":"Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50:485-489.","DOI":"10.1136\/gut.50.4.485"},{"key":"ref199","doi-asserted-by":"crossref","unstructured":"Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47-53.","DOI":"10.1136\/gut.2005.068809"},{"key":"ref200","doi-asserted-by":"crossref","unstructured":"Mantzaris GJ, Sfakianakis M, Archavlis E, Petraki K, Christidou A, Karagiannidis A, Triadaphyllou G. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004;99:1122-1128.","DOI":"10.1111\/j.1572-0241.2004.11481.x"},{"key":"ref201","doi-asserted-by":"crossref","unstructured":"Campbell S, Ghosh S. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. Eur J Gastroenterol Hepatol 2001;13:1297-1301.","DOI":"10.1097\/00042737-200111000-00006"},{"key":"ref202","doi-asserted-by":"crossref","unstructured":"Cummings JR, Herrlinger KR, Travis SP, Gorard DA, McIntyre AS, Jewell DP. Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther 2005;21:385-389.","DOI":"10.1111\/j.1365-2036.2005.02331.x"},{"key":"ref203","doi-asserted-by":"crossref","unstructured":"Paoluzi OA, Pica R, Marcheggiano A, Crispino P, Iacopini F, Iannoni C, Rivera M, Paoluzi P. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 2002;16:1751-1759.","DOI":"10.1046\/j.1365-2036.2002.01340.x"},{"key":"ref204","doi-asserted-by":"crossref","unstructured":"Oren R, Arber N, Odes S, Moshkowitz M, Keter D, Pomeranz I, Ron Y, Reisfeld I, Broide E, Lavy A. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110:1416-1421.","DOI":"10.1053\/gast.1996.v110.pm8613046"},{"key":"ref205","doi-asserted-by":"crossref","unstructured":"Jani N, Regueiro MD. Medical therapy for ulcerative colitis. Gastroenterol Clin North Am 2002;31:147-166.","DOI":"10.1016\/S0889-8553(01)00010-3"},{"key":"ref206","doi-asserted-by":"crossref","unstructured":"Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990;336:16-19.","DOI":"10.1016\/0140-6736(90)91521-B"},{"key":"ref207","doi-asserted-by":"crossref","unstructured":"Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-1845.","DOI":"10.1056\/NEJM199406303302601"},{"key":"ref208","unstructured":"Kornbluth A, Lichtiger S, Present D, et al Long-term results of oral cyclosporine in patients with severe ulcerative colitis: a double-blind randomized, multi-center trial. Gastroenterology 1994;106:A714."},{"key":"ref209","doi-asserted-by":"crossref","unstructured":"Poritz LS, Rowe WA, Swenson BR, Hollenbeak CS, Koltun WA. Intravenous cyclosporine for the treatment of severe steroid refractory ulcerative colitis: what is the cost? Dis Colon Rectum 2005;48:1685-1690.","DOI":"10.1007\/s10350-005-0128-3"},{"key":"ref210","doi-asserted-by":"crossref","unstructured":"McCormack G, McCormick PA, Hyland JM, O'Donoghue DP. Cyclosporin therapy in severe ulcerative colitis: is it worth the effort? Dis Colon Rectum 2002;45:1200-1205.","DOI":"10.1007\/s10350-004-6393-8"},{"key":"ref211","doi-asserted-by":"crossref","unstructured":"Hyde GM, Thillainayagam AV, Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur J Gastroenterol Hepatol 1998;10:411-413.","DOI":"10.1097\/00042737-199805000-00010"},{"key":"ref212","doi-asserted-by":"crossref","unstructured":"Carbonnel F, Boruchowicz A, Duclos B, Soule JC, Lerebours E, Lemann M, Belaiche J, Colombel JF, Cosnes J, Gendre JP. Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses. Dig Dis Sci 1996;41:2471-2476.","DOI":"10.1007\/BF02100145"},{"key":"ref213","doi-asserted-by":"crossref","unstructured":"Message L, Bourreille A, Laharie D, Quinton A, Galmiche JP, Lamouliatte H, Alamdari A, Zerbib F. Efficacy of intravenous cyclosporin in moderately severe ulcerative colitis refractory to steroids. Gastroenterol Clin Biol 2005;29:231-235.","DOI":"10.1016\/S0399-8320(05)80754-7"},{"key":"ref214","unstructured":"Fernandez-Banares F, Bertran X, Esteve-Comas M, Cabre E, Menacho M, Humbert P, Planas R, Gassull MA. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996;91:2498-2499."},{"key":"ref215","doi-asserted-by":"crossref","unstructured":"Campbell S, Ghosh S. Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: the Edinburgh experience of outcome. Dig Liver Dis 2003;35:546-551.","DOI":"10.1016\/S1590-8658(03)00270-6"},{"key":"ref216","doi-asserted-by":"crossref","unstructured":"Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999;94:1587-1592.","DOI":"10.1111\/j.1572-0241.1999.01149.x"},{"key":"ref217","doi-asserted-by":"crossref","unstructured":"Domenech E, Garcia-Planella E, Bernal I, Rosinach M, Cabre E, Fluvia L, Boix J, Gassull MA. Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2002;16:2061-2065.","DOI":"10.1046\/j.1365-2036.2002.01385.x"},{"key":"ref218","doi-asserted-by":"crossref","unstructured":"Rayner CK, McCormack G, Emmanuel AV, Kamm MA. Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis. Aliment Pharmacol Ther 2003;18:303-308.","DOI":"10.1046\/j.1365-2036.2003.01618.x"},{"key":"ref219","doi-asserted-by":"crossref","unstructured":"Actis GC, Ottobrelli A, Pera A, Barletti C, Ponti V, Pinna-Pintor M, Verme G. Continuously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids. J Clin Gastroenterol 1993;17:10-13.","DOI":"10.1097\/00004836-199307000-00004"},{"key":"ref220","doi-asserted-by":"crossref","unstructured":"Van Assche G, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, Arts J, D'Hoore A, Penninckx F, Rutgeerts P. Randomized, double-blind comparison of 4 mg\/kg versus 2 mg\/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025-1031.","DOI":"10.1016\/S0016-5085(03)01214-9"},{"key":"ref221","doi-asserted-by":"crossref","unstructured":"Actis GC, Aimo G, Priolo G, Moscato D, Rizzetto M, Pagni R. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis 1998;4:276-279.","DOI":"10.1097\/00054725-199811000-00003"},{"key":"ref222","unstructured":"Actis GC, Lagget M, Rizzetto M, Fadda M, Palmo A, Pinna-Pintor M, Morino F. Long-term efficacy of oral microemulsion cyclosporin for refractory ulcerative colitis. Minerva Med 2004;95:65-70."},{"key":"ref223","doi-asserted-by":"crossref","unstructured":"de Saussure P, Soravia C, Morel P, Hadengue A. Low-dose oral microemulsion ciclosporin for severe, refractory ulcerative colitis. Aliment Pharmacol Ther 2005;22:203-208.","DOI":"10.1111\/j.1365-2036.2005.02552.x"},{"key":"ref224","doi-asserted-by":"crossref","unstructured":"D'Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, Peeters M, Vermeire S, Penninckx F, Nevens F. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323-1329.","DOI":"10.1053\/gast.2001.23983"},{"key":"ref225","doi-asserted-by":"crossref","unstructured":"Rowe FA, Walker JH, Karp LC, Vasiliauskas EA, Plevy SE, Targan SR. Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol 2000;95:2000-2008.","DOI":"10.1111\/j.1572-0241.2000.02186.x"},{"key":"ref226","unstructured":"Cacheux W, Lemann M, Marteau P, Seksik P, Nion-Larmurier I, Afchain P, Allez M, Daniel F, Beaugerie L, Gendre JP. Predictive factors of response to cyclosporine (CsA) in severe steroid-refractory ulcerative colitis (SSRUC). Gastroenterology 2006;130:A143."},{"key":"ref227","unstructured":"Kornbluth A, Present DH, Lichtiger S, Hanauer S. Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol 1997;92:1424-1428."},{"key":"ref228","doi-asserted-by":"crossref","unstructured":"Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55:1255-1262.","DOI":"10.1136\/gut.2005.081794"},{"key":"ref229","doi-asserted-by":"crossref","unstructured":"Fellermann K, Steffen M, Stein J, Raedler A, Hamling J, Ludwig D, Loeschke K, Stange EF. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:171-176.","DOI":"10.1046\/j.1365-2036.2000.00695.x"},{"key":"ref230","doi-asserted-by":"crossref","unstructured":"Ford AC, Towler RJ, Moayyedi P, Chalmers DM, Axon AT. Mycophenolate mofetil in refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003;17:1365-1369.","DOI":"10.1046\/j.1365-2036.2003.01581.x"},{"key":"ref231","doi-asserted-by":"crossref","unstructured":"Orth T, Peters M, Schlaak JF, Krummenauer F, Wanitschke R, Mayet WJ, Galle PR, Neurath MF. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 2000;95:1201-1207.","DOI":"10.1111\/j.1572-0241.2000.02010.x"},{"key":"ref232","doi-asserted-by":"crossref","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-2476.","DOI":"10.1056\/NEJMoa050516"},{"key":"ref233","doi-asserted-by":"crossref","unstructured":"Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, Vilien M, Strom M, Danielsson A, Verbaan H. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-1811.","DOI":"10.1053\/j.gastro.2005.03.003"},{"key":"ref234","unstructured":"Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized ulcerative colitis patients failing intravenous corticosteroids. Gastroenterology 2006;130:A655."},{"key":"ref235","unstructured":"Lees C, Shand AG, Penman ID, Arnott ID, Satsang J. Infliximab is effective as rescue therapy for acute severe ulcerative colitis: the initial Edinburgh experience. Gastroenterology 2006;130:A656."},{"key":"ref236","unstructured":"Walsh A, Cooley R, Templeton D, Florin T, Radford-Smith G. Acute severe ulcerative colitis: a study of predictors of outcome and efficacy for cyclosporin and infliximab. Gastroenterology 2006;130:A84."},{"key":"ref237","doi-asserted-by":"crossref","unstructured":"Gordon FH, Hamilton MI, Donoghue S, Greenlees C, Palmer T, Rowley-Jones D, Dhillon AP, Amlot PL, Pounder RE. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002;16:699-705.","DOI":"10.1046\/j.1365-2036.2002.01205.x"},{"key":"ref238","doi-asserted-by":"crossref","unstructured":"van Assche G, Rutgeerts P. Antiadhesion molecule therapy in inflammatory bowel disease. Inflamm Bowel Dis 2002;8:291-300.","DOI":"10.1097\/00054725-200207000-00009"},{"key":"ref239","doi-asserted-by":"crossref","unstructured":"Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, Tami J, Yu R, Gibiansky E, Shanahan WR. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002;51:30-36.","DOI":"10.1136\/gut.51.1.30"},{"key":"ref240","doi-asserted-by":"crossref","unstructured":"van Deventer SJ, Tami JA, Wedel MK. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 2004;53:1646-1651.","DOI":"10.1136\/gut.2003.036160"},{"key":"ref241","doi-asserted-by":"crossref","unstructured":"Creed TJ, Norman MR, Probert CS, Harvey RF, Shaw IS, Smithson J, Anderson J, Moorghen M, Gupta J, Shepherd NA. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003;18:65-75.","DOI":"10.1046\/j.1365-2036.2003.01639.x"},{"key":"ref242","unstructured":"Walker KB, Potter JM, House AK. Interleukin 2 synthesis in the presence of steroids: a model of steroid resistance. Clin Exp Immunol 1987;68:162-167."},{"key":"ref243","doi-asserted-by":"crossref","unstructured":"Van Assche G, Dalle I, Noman M, Aerden I, Swijsen C, Asnong K, Maes B, Ceuppens J, Geboes K, Rutgeerts P. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003;98:369-376.","DOI":"10.1016\/S0002-9270(02)05907-5"},{"key":"ref244","doi-asserted-by":"crossref","unstructured":"Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson FH, Valentine JF, Wild GE. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 2006;55:1568-1574.","DOI":"10.1136\/gut.2005.089854"},{"key":"ref245","doi-asserted-by":"crossref","unstructured":"Plevy S, Regueiro M, et al. A humanized ant-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid-refractory ulcerative colitis: results of a phase I study. Gastroenterology 2004;126:A75.","DOI":"10.1016\/S0016-5085(03)80033-1"},{"key":"ref246","doi-asserted-by":"crossref","unstructured":"Carpenter PA, Appelbaum FR, Corey L, Deeg HJ, Doney K, Gooley T, Krueger J, Martin P, Pavlovic S, Sanders J. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002;99:2712-2719.","DOI":"10.1182\/blood.V99.8.2712"},{"key":"ref247","doi-asserted-by":"crossref","unstructured":"Tilg H, Vogelsang H, Ludwiczek O, Lochs H, Kaser A, Colombel JF, Ulmer H, Rutgeerts P, Kruger S, Cortot A. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003;52:1728-1733.","DOI":"10.1136\/gut.52.12.1728"},{"key":"ref248","unstructured":"Cottone M, Magliocco A, Trallori G, Brignola C, Vandelli C, Ardizzone S, Meucci G, Zannoni F, Di Maio G, Astegiano M. Clinical course of inflammatory bowel disease during treatment with interferon for associated chronic active hepatitis. Ital J Gastroenterol 1995;27:3-4."},{"key":"ref249","doi-asserted-by":"crossref","unstructured":"Bargiggia S, Thorburn D, Anderloni A, Ardizzone S, Giorgi A, Bianchi Porro G, Parente F. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study. Aliment Pharmacol Ther 2005;22:209-215.","DOI":"10.1111\/j.1365-2036.2005.02556.x"},{"key":"ref250","unstructured":"Sumer N, Palabiyikoglu M. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 1995;7:597-602."},{"key":"ref251","doi-asserted-by":"crossref","unstructured":"Madsen SM, Schlichting P, Davidsen B, Nielsen OH, Federspiel B, Riis P, Munkholm P. An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am J Gastroenterol 2001;96:1807-1815.","DOI":"10.1111\/j.1572-0241.2001.03875.x"},{"key":"ref252","doi-asserted-by":"crossref","unstructured":"Musch E, Andus T, Malek M. Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial. Aliment Pharmacol Ther 2002;16:1233-1239.","DOI":"10.1046\/j.1365-2036.2002.01264.x"},{"key":"ref253","doi-asserted-by":"crossref","unstructured":"Nikolaus S, Rutgeerts P, Fedorak R, Steinhart AH, Wild GE, Theuer D, Mohrle J, Schreiber S. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut 2003;52:1286-1290.","DOI":"10.1136\/gut.52.9.1286"},{"key":"ref254","doi-asserted-by":"crossref","unstructured":"Musch E, Andus T, Kruis W, Raedler A, Spehlmann M, Schreiber S, Krakamp B, Malek M, Malchow H, Zavada F. Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2005;3:581-586.","DOI":"10.1016\/S1542-3565(05)00208-9"},{"key":"ref255","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Sands BE, Wolf DC, Valentine JF, Safdi M, Katz S, Isaacs KL, Wruble LD, Katz J, Present DH. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther 2003;17:1355-1364.","DOI":"10.1046\/j.1365-2036.2003.01589.x"},{"key":"ref256","doi-asserted-by":"crossref","unstructured":"Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003;349:350-357.","DOI":"10.1056\/NEJMoa013136"},{"key":"ref257","unstructured":"Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 1998;43:5S-13S."},{"key":"ref258","doi-asserted-by":"crossref","unstructured":"Makiyama K, Takeshima F, Hamamoto T. Efficacy of rebamipide enemas in active distal ulcerative colitis and proctitis: a prospective study report. Dig Dis Sci 2005;50:2323-2329.","DOI":"10.1007\/s10620-005-3055-1"},{"key":"ref259","unstructured":"Hanai H, Iida T, Takeuchi K, Yamada M, Iwaoka , Y , Andoh A, Tujikawa T, Fujiyama Y, Watanbe F. Curcumin, a promising drug for long-term maintenance therapy in patients with ulcerative colitis: results from a multicenter, randomized double-blind placebo-controlled clinical trial. Gastroenterology 2006;130:A84."},{"key":"ref260","doi-asserted-by":"crossref","unstructured":"Regueiro M, Kip KE, Cheung O, Hegazi RA, Plevy S. Cigarette smoking and age at diagnosis of inflammatory bowel disease. Inflamm Bowel Dis 2005;11:42-47.","DOI":"10.1097\/00054725-200501000-00006"},{"key":"ref261","doi-asserted-by":"crossref","unstructured":"Abraham N, Selby W, Lazarus R, Solomon M. Is smoking an indirect risk factor for the development of ulcerative colitis? An age- and sex-matched case-control study. J Gastroenterol Hepatol 2003;18:139-146.","DOI":"10.1046\/j.1440-1746.2003.02953.x"},{"key":"ref262","doi-asserted-by":"crossref","unstructured":"Birrenbach T, Bocker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm Bowel Dis 2004;10:848-859.","DOI":"10.1097\/00054725-200411000-00019"},{"key":"ref263","doi-asserted-by":"crossref","unstructured":"McGrath J, McDonald JW, Macdonald JK. Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2004;CD004722.","DOI":"10.1002\/14651858.CD004722.pub2"},{"key":"ref264","doi-asserted-by":"crossref","unstructured":"Thomas GA, Rhodes J, Mani V, Williams GT, Newcombe RG, Russell MA, Feyerabend C. Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 1995;332:988-992.","DOI":"10.1056\/NEJM199504133321503"},{"key":"ref265","doi-asserted-by":"crossref","unstructured":"Ingram JR, Thomas GA, Rhodes J, Green JT, Hawkes ND, Swift JL, Srivastava ED, Evans BK, Williams GT, Newcombe RG. A randomized trial of nicotine enemas for active ulcerative colitis. Clin Gastroenterol Hepatol 2005;3:1107-1114.","DOI":"10.1016\/S1542-3565(05)00849-9"},{"key":"ref266","doi-asserted-by":"crossref","unstructured":"Katz S. Update in medical therapy of ulcerative colitis: newer concepts and therapies. J Clin Gastroenterol 2005;39:557-569.","DOI":"10.1097\/01.mcg.0000170735.43887.3a"},{"key":"ref267","doi-asserted-by":"crossref","unstructured":"Sawada K, Muto T, Shimoyama T, Satomi M, Sawada T, Nagawa H, Hiwatashi N, Asakura H, Hibi T. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 2003;9:307-321.","DOI":"10.2174\/1381612033391928"},{"key":"ref268","doi-asserted-by":"crossref","unstructured":"Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, Tozawa K, Tanaka T, Maruyama Y, Matsushita I. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 2004;70:36-44.","DOI":"10.1159\/000080079"},{"key":"ref269","doi-asserted-by":"crossref","unstructured":"Sawada K, Kusugami K, Suzuki Y, Bamba T, Munakata A, Hibi T, Shimoyama T. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 2005;100:1362-1369.","DOI":"10.1111\/j.1572-0241.2005.41089.x"},{"key":"ref270","doi-asserted-by":"crossref","unstructured":"Takemoto K, Kato J, Kuriyama M, Nawa T, Kurome M, Okada H, Sakaguchi K, Shiratori Y. Predictive factors of efficacy of leukocytapheresis for steroid-resistant ulcerative colitis patients. Dig Liver Dis 2007;39:422-429.","DOI":"10.1016\/j.dld.2007.01.010"},{"key":"ref271","doi-asserted-by":"crossref","unstructured":"Hanai H, Watanabe F, Takeuchi K, Iida T, Yamada M, Iwaoka Y, Saniabadi A, Matsushita I, Sato Y, Tozawa K. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 2003;1:28-35.","DOI":"10.1053\/jcgh.2003.50005"},{"key":"ref272","doi-asserted-by":"crossref","unstructured":"Sawada K, Egashira A, Ohnishi K, Fukunaga K, Kusaka T, Shimoyama T. Leukocytapheresis (LCAP) for management of fulminant ulcerative colitis with toxic megacolon. Dig Dis Sci 2005;50:767-773.","DOI":"10.1007\/s10620-005-2571-3"},{"key":"ref273","unstructured":"Sakuraba A, Sato T, Iwakami Y, Takada Y, Inoue N, Takaishi M, Ogata H, Iwao , Hibi T. An open-labeled trial of granulocyte and monocyte adsorption apheresis for pouchitis. Gastroenterology 2006;130:A661."},{"key":"ref274","doi-asserted-by":"crossref","unstructured":"Fujimoto E, Fujimoto N, Kuroda K, Tajima S. Leukocytapheresis treatment for pyoderma gangrenosum. Br J Dermatol 2004;151:1090-1092.","DOI":"10.1111\/j.1365-2133.2004.06249.x"},{"key":"ref275","doi-asserted-by":"crossref","unstructured":"Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005;100:1539-1546.","DOI":"10.1111\/j.1572-0241.2005.41794.x"},{"key":"ref276","doi-asserted-by":"crossref","unstructured":"Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003;15:697-698.","DOI":"10.1097\/00042737-200306000-00017"},{"key":"ref277","doi-asserted-by":"crossref","unstructured":"Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, Otsuka M, Hasunuma O, Kurihara R, Iwasaki A. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004;20:1133-1141.","DOI":"10.1111\/j.1365-2036.2004.02268.x"},{"key":"ref278","doi-asserted-by":"crossref","unstructured":"Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'neil DA, Macfarlane GT. Synbiotic therapy (Bifidobacterium longum\/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005;54:242-249.","DOI":"10.1136\/gut.2004.044834"},{"key":"ref279","doi-asserted-by":"crossref","unstructured":"Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, Kamm MA, Weismueller J, Beglinger C, Stolte M. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617-1623.","DOI":"10.1136\/gut.2003.037747"},{"key":"ref280","doi-asserted-by":"crossref","unstructured":"Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006;23:1567-1574.","DOI":"10.1111\/j.1365-2036.2006.02927.x"},{"key":"ref281","doi-asserted-by":"crossref","unstructured":"Summers RW, Elliott DE, Urban JF Jr, Thompson RA, Weinstock JV. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 2005;128:825-832.","DOI":"10.1053\/j.gastro.2005.01.005"},{"key":"ref282","doi-asserted-by":"crossref","unstructured":"Mayer L. A novel approach to the treatment of ulcerative colitis: is it kosher? Gastroenterology 2005;128:1117-1119.","DOI":"10.1053\/j.gastro.2005.02.038"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v14\/i3\/354.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T01:11:10Z","timestamp":1630545070000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v14\/i3\/354.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":282,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.14.354","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2008]]}}}